IMMU-132 Product Royalty Term. Licensee’s obligation to pay a royalty under Section 8.7(a) for a particular IMMU-132 Product shall be in effect in each country of sale from First Commercial Sale in the country and shall expire, on a country-by-country and product-by-product basis, on the later of (i) *** and (ii) ***.
Appears in 3 contracts
Samples: Development and License Agreement (Immunomedics Inc), Development and License Agreement (Immunomedics Inc), Development and License Agreement (Immunomedics Inc)
IMMU-132 Product Royalty Term. Licensee’s obligation to pay a royalty under Section 8.7(a) for a particular IMMU-132 Product shall be in effect in each country of sale from First Commercial Sale in the country and shall expire, on a country-by-country and product-by-product basis, on the later of (i) **[ * ] and (ii) ***[ * ].
Appears in 1 contract
Samples: Development and License Agreement (Seattle Genetics Inc /Wa)
